To better understand the selection of CIGB-552 as a new anticancer peptide, the effect on NF-κB mediated transcription of both peptides was evaluated in two reporter cell lines derived from H460 and HT-29 cancer cells [15,16]. The gene discussed is NFKB1; the disease is cancer.